Janice McCourt - 14 Oct 2023 Form 4 Insider Report for Comera Life Sciences Holdings, Inc.

Reporting relationship: Chief Business Officer
Issuer ticker: N/A
Reported as of: 14 Oct 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Oct 2023, 16:59:06 UTC
Prior SEC filing: 09 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Ryan M. Rourke Reed, Attorney-in-Fact

Key filing fact

Janice McCourt filed Form 4 for Comera Life Sciences Holdings, Inc. on 16 Oct 2023.

Key facts

This page summarizes Janice McCourt's Form 4 filing for Comera Life Sciences Holdings, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Oct 2023, 16:59.

Change

Previous filing in this sequence was filed on 09 Nov 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CMRA transaction Derivative

Stock Option (Right to Purchase)

Award

Transaction value: $0
Shares: +20,000
Change %
Price: $0.000000
Shares after: 20,000
Date: 14 Oct 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $0.2900
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Janice McCourt is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

On October 4, 2023, the reporting person was granted an option to purchase 20,000 shares of common stock of the issuer. The option vested in full following the satisfaction of certain performance criteria including the execution of a separation agreement and release by the reporting person and the expiration of a seven-day revocation period without the reporting person revoking the separation agreement and release.